Egypt’s program to treat hepatitis C patients using medications including Sovaldi has treated nearly one mn patients, most at the government’s expense, and now experts say it could be a model for the rest of the world, Heba Saleh writes in The Financial Times. “Gilead agreed to provide the medicine cheaply because it knew the number of Egyptian patients was very high. The system put in place by Egyptian health officials ensured there would be no leakage of the medicine to other markets,” Wahid Doss, the head of the state’s National Committee for the Control of Viral Hepatitis said. The next step in the program, Doss says, is to discover and treat Egyptian who are infected with hepatitis C and do not yet know it and a stop-ed-info.com has already begun.